试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-02
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
编号:NCT03872388登记状态:提前终止企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Atorvastatin、Capecitabine
登记的停止原因(原文):Due to slow accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-02
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
编号:NCT04683939登记状态:提前终止企业 / 申办者:BioNTech SE
药物 / 成分:BNT141、Nab-paclitaxel、Gemcitabine
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-02
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
编号:NCT04776018登记状态:提前终止企业 / 申办者:Takeda
药物 / 成分:TAK-981、Mezagitamab、Daratumumab and Hyaluronidase-fihj
登记的停止原因(原文):Business Reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-02
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
编号:NCT05835011登记状态:提前终止企业 / 申办者:Astex Pharmaceuticals, Inc.
药物 / 成分:Decitabine/Cedazuridine、Magrolimab
登记的停止原因(原文):Termination due to discontinuation of magrolimab development in MDS.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-01
Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water
编号:NCT01246869登记状态:提前终止企业 / 申办者:University of Utah
药物 / 成分:[18F]fluoro-2-deoxy-D-glucose (FDG)、1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole、[15O]water、Magnetic Resonance Imaging
登记的停止原因(原文):PI retired, study closed
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-01
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
编号:NCT02548351登记状态:提前终止企业 / 申办者:Intercept Pharmaceuticals
药物 / 成分:Obeticholic Acid、Placebo
登记的停止原因(原文):The FDA issued a CRL in response to Intercept's NDA for OCA for the treatment of NASH. Sponsor decided to terminate 747-303 before the planned completion date.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-01
Ruxolitinib and Steroid As First Line Therapy for Acute GVHD
编号:NCT03701698登记状态:提前终止企业 / 申办者:Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
药物 / 成分:Ruxolitinib Oral Tablet、Methylprednisolone
登记的停止原因(原文):Participants recruitment failure
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-01
A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
编号:NCT04325698登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:PF-06439535 (CN)、Bevacizumab-EU、Paclitaxel、Carboplatin
登记的停止原因(原文):The study was terminated as part of the decision by Pfizer to halt its biosimilars programs in China.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-01
A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)
编号:NCT04521621登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:Gebasaxturev、Pembrolizumab
登记的停止原因(原文):Business Reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-01
3M Oral Rinse Incidence and Patient Acceptance of Sloughing When Used With Sodium Lauryl Sulfate (SLS) Toothpastes
编号:NCT04601103登记状态:提前终止企业 / 申办者:Solventum US LLC
药物 / 成分:No SLS toothpaste、Medium SLS toothpaste、High SLS toothpaste、Anti-plaque
登记的停止原因(原文):Device Deficiency
查看官方原始记录 ↗